Cardialen has been awarded a US$2.8 million National Institutes of Health (NIH) phase II SBIR grant to further the clinical study of low-energy cardioversion of atrial fibrillation (AF) in human subjects in the USA.
The grant was awarded after a panel of cardiologists, scientists, and engineers gave the Cardialen therapy an exceptional peer review as part of a competitive grant process.
John Hummel, a clinical researcher at The Ohio State University Wexner Medical Center, Columbus, USA specialising in the treatment of AF, is the principal investigator of this NIH-funded, multicentre clinical study. “Atrial fibrillation remains a serious arrhythmia, and additional treatment options are needed,” said Hummel. “The early positive results from Cardialen’s acute clinical study are very promising. I am pleased to be the principal investigator for this important study, which is designed to evaluate therapeutic safety and efficacy in an acute clinical setting.”
AF is an irregular and rapid heart rate that can lead to patient discomfort and increased risk of stroke. Approximately 34 million patients suffer from this condition worldwide. Cardialen seeks to provide a therapy for patients already receiving an implantable defibrillator device.